Sunshine Biopharma, Inc. (Nasdaq: SBFM) has released its 2023 First Quarter Results, showcasing impressive growth. The company reported gross revenues of $4,894,053 as of March 31, 2023, marking an exceptional increase of more than 2,100% compared to the same period in 2022. This substantial growth has sparked investor interest, with the stock trading at $0.99 in pre-market, up $0.49 or an astonishing 97.8627%.

In other news, Jaguar Health, Inc. (Nasdaq: JAGX) has announced that its FDA conditionally approved prescription drug product, Canalevia-CA1, for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is now available on Chewy. Chewy, known as a trusted destination for pet parents and partners, provides a convenient platform for pet owners to access this important treatment option. This news has contributed to a positive market response, with the stock trading at $0.91 in pre-market, up $0.19 or 26.39%.

Furthermore, Albemarle Corporation (NYSE: ALB) has received an upgrade from KeyBanc Capital Markets, going from Sector Weight to Overweight. This upgrade indicates a positive outlook for the company, potentially boosting investor confidence. Currently, the stock is trading at $196.85 in pre-market, up $2.34 or 1.20%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)